References
Williams JD. Quo vadis with bacterial resistance? Drugs 1995; 49 Suppl. 2: 1–9
Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 1995 Dec; 13(6): 343–58
Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946–50
Rubinstein E. Tolerance of sparfloxacin. Sparfloxacin Symposium. Rhone Poulenc Rorer; 1995 Jun 24–25; Seville
Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. N Engl J Med 1994; 331: 748
Lee WT, Collins JF. Ciprofloxacin associated bilateral tendon rupture. Aust NZ J Med 1992; 22: 500
MacEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. Lancet 1988; ii: 900
Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendonitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992; 19: 1479–81
Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193
Schaad U, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy Commission. Pediatr Infect Dis J 1995; 14: 1–9
Chysky V, Kapila K, Jullman G, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991; 19: 289–96
Pradhan KM, Arora NK, Jena A, et al. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr 1995; 84: 555–60
Schaad UB, Sander E, Wedgwood J, et al. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992; 11: 1047–9
Bouissou H, Caujolle D, Caujolle F, et al. Toxicologie experimentale. Tissus cartilagineux et acide nalidixique. C R Acad Sci Hebd Seances Acad Sci D 1978; 286: 1743–6
Gough A, Barsoum NJ, Mitchell L, et al. Juvenile canine druginduced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979; 51: 177–87
Ingham B, Brentnall DW, Dale EA, et al. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 1: 21–6
McDonald DF, Short HB. Usefulness of nalidixic acid in treatment of urinary infection. Antimicrob Agents Chemother 1964; 4: 628–31
Ribard P, Kahn MF. Rheumatological side-effects of quinolones. In: Kahn MF, editor. Baillière’s clinical rheumatology: drug-induced rheumatic diseases. London: Baillière Tindall, 1991: 175–91
Chevalier X, Albengres E, Voisin MC, et al. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf 1992; 7: 310–4
Pertuiset E, Lenoir G, Jehanne M, et al. Tolérance articulaire de la péfloxacine et de l’ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhum Mal Osteoartic 1989; 56: 735–40
Schaad UB, Stoupis C, Wedgwood J, et al. et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991; 10: 723–9
Tatsumi H, Senda H, Yatera S, et al. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci 1978; 3: 357–67
Burkhardt JE, Hill MA, Turek JJ, et al. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1992; 29: 230–8
Stahlmann R, Merker HJ, Hinz N, et al. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol 1990; 64: 193–204
Burkhardt JE, Hill MA, Carlton WW, et al. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990; 27: 162–70
Machida M, Kusajima H, Aijima H, et al. Toxokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol Appl Pharmacol 1990; 105: 403–12
Hayem G, Petit PX, Levacher M, et al. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 1994; 38: 243–7
Thuong-Guyot M, Domarle O, Pocidalo JJ, et al. Effects of fluoroquinolones on cultured articular chondrocytes. Flow cytometric analysis of free radical production. J Pharmacol Exp Ther 1994; 271: 1544–9
Bendele AM, Hulman JF, Harvey AK, et al. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol Pathol 1990; 18: 304–12
Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8
Perrot S, Ziza JM, De Bourran-Cauet G, et al. Nouvelle complication liée aux quinolones: la rupture du tendon d’Achille. Presse Med 1991; 20: 1234
Kato M, Takeda S, Kashida Y, et al. Histological examination of Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Path 1995; 23: 385–92
Bailey RR, Kirk JA, Peddie B A. Norfloxacin induced rheumatic disease. NZ Med J 1983; 96: 590
Bailey RR, Peddie BA. Enoxacin for the treatment of urinary tract infection. NZ Med J 1985; 98: 286–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hayem, G., Carbon, C. A Reappraisal of Quinolone Tolerability. Drug-Safety 13, 338–342 (1995). https://doi.org/10.2165/00002018-199513060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199513060-00003